Complicated biomolecules call for alternative drug delivery strategies.

Next-Gen Technologies Tackle Drug Delivery Challenges

Miniaturized high-throughput screening is applicable to bispecific antibody development.

Picodroplet Technology Applications in Cell Line Development

The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.

Next-Gen Therapies Drive Development Technologies

Topic

Articles

Recordati’s blockbuster acquisition of EUSA Pharma gives them access to a portfolio of four drugs that treat rare cancers.

Recordati Acquires EUSA Pharma for $845 Million

This collaboration aims to better understand Alzheimer’s and Parkinson’s disease and increase drug discovery and development success rates.

GSK and the University of Oxford Join Forces to Research Treatment Potentials for Neurological Diseases

 Washington Editor, jillwechsler7@gmail.com.

High price tags threaten to block patient access to potentially life-saving cures and treatments.

FDA Grapples with the Promise and Perils of Gene Therapy

Fujifilm’s center adds local support in Suzhou, China for cell culture media optimization.

Fujifilm Irvine Scientific Builds Bioprocessing Innovation and Collaboration Center in China

EMA has fully validated the marketing authorization application for Atara Biotherapeutics’ off-the-shelf allogeneic T-cell therapy, tab-cel (tabelecleucel), with an approval decision expected in 2022.

Atara Biotherapeutics' MAA for Allogeneic T-cell Immunotherapy Gets EMA Validation

Chinook Therapeutics has formed a 50/50 joint venture with investors to develop kidney disease therapies in China.

Chinook Therapeutics and Investors Form Joint Venture for Kidney Disease Therapies

Raymond P. Goodrich, PhD, is the founder of PhotonPharma, executive director of the infectious disease research center at Colorado State University, and professor for the department of microbiology, immunology, and pathology at Colorado State University.

Amanda Guth, DVM, PhD, is the chief scientific officer for PhotonPharma.

Jon Weston is the president and CEO of PhotonPharma.

Terry Opgenorth, PhD, is the executive in residence life sciences for CSU Ventures.

Gary Gordon, MD, PhD, is the president of Global Coalition for Adaptive Research.

Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.

Formulating Autologous Therapies for Cancer

Feliza Mirasol is the science editor for 

Glycosylation monitoring has been heavily dependent on manual processes, but the automation of sample preparation streamlines the overall workflow.

Streamlining Glycosylation Monitoring through Automation

COVID-19 is refocusing calls for new tools and urgent therapeutic responses.

Biotech Startups Seeing Renewed Interest Following Pandemic

BeiGene has acquired property in Hopewell, NJ to build a new manufacturing site and clinical R&D center for advanced new medicines.